Comparison of Seattle Genetics Inc. (SGEN) and Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

This is therefore a contrasting of the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation in Seattle Genetics Inc. (NASDAQ:SGEN) and Milestone Pharmaceuticals Inc. (NASDAQ:MIST). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seattle Genetics Inc. 108 -3.27 119.50M -1.75 0.00
Milestone Pharmaceuticals Inc. 19 0.00 7.60M -73.12 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Seattle Genetics Inc. 110,719,911.05% -21.4% -18%
Milestone Pharmaceuticals Inc. 40,663,456.39% 0% 0%

Liquidity

3 and 2.7 are the respective Current Ratio and a Quick Ratio of Seattle Genetics Inc. Its rival Milestone Pharmaceuticals Inc.’s Current and Quick Ratios are 18.6 and 18.6 respectively. Milestone Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Seattle Genetics Inc.

Analyst Ratings

Recommendations and Ratings for Seattle Genetics Inc. and Milestone Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Seattle Genetics Inc. 0 2 9 2.82
Milestone Pharmaceuticals Inc. 0 0 0 0.00

Seattle Genetics Inc. has a consensus target price of $108.92, and a -7.97% downside potential.

Institutional and Insider Ownership

Institutional investors owned 0% of Seattle Genetics Inc. shares and 59.9% of Milestone Pharmaceuticals Inc. shares. Seattle Genetics Inc.’s share owned by insiders are 1.1%. Comparatively, 23.6% are Milestone Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Seattle Genetics Inc. 2.91% 10.77% 13% 0.77% 8.86% 33.62%
Milestone Pharmaceuticals Inc. -17.43% -37.6% 0% 0% 0% 5.4%

For the past year Seattle Genetics Inc.’s stock price has bigger growth than Milestone Pharmaceuticals Inc.

Summary

Seattle Genetics Inc. beats Milestone Pharmaceuticals Inc. on 7 of the 11 factors.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.